GLP-1 RA Cohort Among patients still under observation at 12 months, 52.0% were receiving treatment at 1 year (Fig
7 Still, Le, who is also a general surgery registrar at Royal Melbourne Hospital, says, I think it is too early to say this is a robust, durable, and generalizable effect given the high heterogeneity of underlying studies. He notes a need for more rigorous randomized controlled trials with longer follow-up times to better characterize the impact of these medications on weight and OSA together, as well as gain a better understanding of effect size, optimal doses, side effects, interactions with other medications, and impacts on other comorbidities

Furthermore, a key limitation of this study is the absence of in-depth exploration into the molecular mechanisms underlying the niosomal formulations of both treatments (QTLN and QTLN), particularly how they enhance male fertility by modulating specific genetic pathways such as Nrf2/HO-1, sperm DNA damage (include assays such as Sperm Chromatin Dispersion (SCD) test or Comet assay for sperm DNA integrity) as well as the lack of evaluation regarding their potential applicability in humans
For travel and on-the-go use, ODTs are the clear winner
Do I need liver function tests whilst taking Ozempic